ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III
An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding…
December 10, 2019 - 2 minutes
An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding…
Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban…
Ernest Loumaye began as a doctor at a university hospital and is now CEO of…
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral…